Mainz Biomed (MYNZ) Competitors $1.60 -0.05 (-3.03%) Closing price 04:00 PM EasternExtended Trading$1.58 -0.03 (-1.56%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MYNZ vs. ITRM, LNAI, AKTX, DARE, CVKD, KZR, RNTX, PMN, XCUR, and ENLVShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include Iterum Therapeutics (ITRM), Lunai Bioworks (LNAI), Akari Therapeutics (AKTX), Dare Bioscience (DARE), Cadrenal Therapeutics (CVKD), Kezar Life Sciences (KZR), Rein Therapeutics (RNTX), Promis Neurosciences (PMN), Exicure (XCUR), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. Its Competitors Iterum Therapeutics Lunai Bioworks Akari Therapeutics Dare Bioscience Cadrenal Therapeutics Kezar Life Sciences Rein Therapeutics Promis Neurosciences Exicure Enlivex Therapeutics Iterum Therapeutics (NASDAQ:ITRM) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership. Do analysts rate ITRM or MYNZ? Iterum Therapeutics currently has a consensus price target of $9.00, suggesting a potential upside of 1,076.78%. Mainz Biomed has a consensus price target of $14.00, suggesting a potential upside of 775.00%. Given Iterum Therapeutics' higher probable upside, analysts plainly believe Iterum Therapeutics is more favorable than Mainz Biomed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ITRM or MYNZ more profitable? Company Net Margins Return on Equity Return on Assets Iterum TherapeuticsN/A N/A -65.01% Mainz Biomed N/A N/A N/A Does the media favor ITRM or MYNZ? In the previous week, Mainz Biomed had 3 more articles in the media than Iterum Therapeutics. MarketBeat recorded 3 mentions for Mainz Biomed and 0 mentions for Iterum Therapeutics. Iterum Therapeutics' average media sentiment score of 0.00 beat Mainz Biomed's score of -0.98 indicating that Iterum Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Iterum Therapeutics Neutral Mainz Biomed Negative Which has better valuation and earnings, ITRM or MYNZ? Mainz Biomed has higher revenue and earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIterum TherapeuticsN/AN/A-$24.77M-$0.85-0.90Mainz Biomed$890K9.73-$21.65M-$65.60-0.02 Do insiders and institutionals hold more shares of ITRM or MYNZ? 9.2% of Iterum Therapeutics shares are owned by institutional investors. 2.4% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, ITRM or MYNZ? Iterum Therapeutics has a beta of 3.24, indicating that its stock price is 224% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. SummaryMainz Biomed beats Iterum Therapeutics on 6 of the 11 factors compared between the two stocks. Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.93M$3.35B$6.11B$10.56BDividend YieldN/A2.29%5.69%4.75%P/E Ratio-0.0221.5785.4827.60Price / Sales9.73476.51624.19239.62Price / CashN/A47.1237.9261.55Price / Book0.6110.1413.136.76Net Income-$21.65M-$52.31M$3.30B$275.88M7 Day Performance2.56%6.72%5.29%3.72%1 Month Performance-2.44%15.01%9.94%10.22%1 Year Performance-86.21%29.34%87.78%35.86% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed2.7953 of 5 stars$1.60-3.0%$14.00+775.0%-84.7%$8.93M$890K-0.0230News CoverageGap UpHigh Trading VolumeITRMIterum Therapeutics1.482 of 5 stars$0.70+4.4%$9.00+1,185.7%-23.1%$31.64MN/A-0.8210Analyst ForecastGap UpLNAILunai BioworksN/A$1.27-1.6%N/AN/A$29.90MN/A-0.1620Analyst ForecastAKTXAkari Therapeutics2.7196 of 5 stars$1.03+11.9%$3.30+222.0%-65.5%$29.88MN/A0.009Analyst ForecastDAREDare Bioscience1.8989 of 5 stars$2.25+3.2%$10.00+344.4%-32.1%$29.39M$10K-1.0530Analyst ForecastHigh Trading VolumeCVKDCadrenal Therapeutics2.3883 of 5 stars$13.53-4.6%$32.00+136.5%+13.4%$29.02MN/A-1.524Analyst ForecastKZRKezar Life Sciences3.5592 of 5 stars$3.93+0.3%$9.00+129.0%-50.1%$28.71M$7M-0.4160Analyst ForecastRNTXRein Therapeutics3.0691 of 5 stars$1.19flat$10.00+740.3%N/A$27.73MN/A-0.449Analyst ForecastPMNPromis Neurosciences3.3456 of 5 stars$0.55+10.2%$4.33+689.6%-50.8%$26.80MN/A-2.615News CoveragePositive NewsAnalyst ForecastGap UpHigh Trading VolumeXCURExicure1.7062 of 5 stars$4.27+2.4%N/A+52.8%$26.34M$500K-1.1050Analyst ForecastGap UpENLVEnlivex Therapeutics2.1604 of 5 stars$1.15+8.0%$10.00+773.4%-26.1%$25.75MN/A-1.9770Analyst ForecastHigh Trading Volume Related Companies and Tools Related Companies Iterum Therapeutics Alternatives Lunai Bioworks Alternatives Akari Therapeutics Alternatives Dare Bioscience Alternatives Cadrenal Therapeutics Alternatives Kezar Life Sciences Alternatives Rein Therapeutics Alternatives Promis Neurosciences Alternatives Exicure Alternatives Enlivex Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYNZ) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersMelt-up warning America’s $37.5 trillion debt spiral, soaring deficits, and repeated credit downgrades are exactly what Porter...Porter & Company | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
